Abstract
1148P Avelumab as second-line or later (2L+) treatment (tx) in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Real-world tx patterns in France
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have